Phenotyping drug disposition in oncology

Cancer Treatment Reviews

Volumn 38, Issue 6, 2012, Pages 715-725

  Opdam, Frans L ^a   Gelderblom, Hans ^a   Guchelaar, Henk Jan ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Anticancer agents; Drug disposition; Drug transporters; Metabolism; Pharmacokinetics; Phase I reactions; Phase II reactions; Phenotyping; Probe

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CAPECITABINE; CARMUSTINE; CARRIER PROTEIN; CHLORAMBUCIL; CISPLATIN; CYCLOPHOSPHAMIDE; DASATINIB; DOCETAXEL; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; FLUOROURACIL; GEFITINIB; IFOSFAMIDE; IMATINIB; IRINOTECAN; LAPATINIB; MELPHALAN; MITOXANTRONE; NAVELBINE; NILOTINIB; OXALIPLATIN; PACLITAXEL; SORAFENIB; SUNITINIB; TAMOXIFEN; THALIDOMIDE; UNINDEXED DRUG;

ANTINEOPLASTIC ACTIVITY; DIARRHEA; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG METABOLISM; ENZYME ACTIVITY; GENETIC VARIABILITY; HUMAN; LEUKOPENIA; NAUSEA; NEOPLASM; NEUTROPENIA; ONCOLOGY; PHENOTYPE; PHENOTYPIC VARIATION; REVIEW; VOMITING;

ANTINEOPLASTIC AGENTS; BIOLOGICAL TRANSPORT; CYTOCHROME P-450 ENZYME SYSTEM; DIHYDROURACIL DEHYDROGENASE (NADP); HUMANS; MEMBRANE TRANSPORT PROTEINS; METABOLIC DETOXICATION, DRUG; NEOPLASMS; PHENOTYPE;

EID: 84861673355     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.12.003     Document Type: Review

References (128)

1. Kalow W., Tang B.K., Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998, 8(4):283-289.
2. Coate L., Cuffe S., Horgan A., Hung R.J., Christiani D., Liu G. Germline genetic variation, cancer outcome, and pharmacogenetics. J Clin Oncol 2010, 28(26):4029-4037.
3. Evans W.E., Mcleod H.L. Drug therapy-pharmacogenomics-drug disposition, drug targets, and side effects. N Engl J Med 2003, 348(6):538-549.
4. Black A.J., Mcleod H.L., Capell H.A., et al. Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine. Ann Intern Med 1998, 129(9):716-718.
5. Dunn J., Baborie A., Alam F., et al. Extent of MGMT promoter methylation correlates with outcome in glioblastomas given temozolomide and radiotherapy. Br J Cancer 2009, 101(1):124-131.
6. Swen J.J., Huizinga T.W., Gelderblom H., et al. Translating pharmacogenomics: challenges on the road to the clinic. PLoS Med 2007, 4(8):1317-1324.
7. Deeken J.F., Figg W.D., Bates S.E., Sparreboom A. Toward individualized treatment: prediction of anticancer drug disposition and toxicity with pharmacogenetics. Anticancer Drugs 2007, 18(2):111-126.
8. Pal S.K., Hurria A. Impact of age, sex, and comorbidity on cancer therapy and disease progression. J Clin Oncol 2010, 28(26):4086-4093.
9. Singh S., Parulekar W., Murray N., et al. Influence of gender on treatment outcome and toxicity in small cell lung cancer (SCLC). J Clin Oncol 2004, 22(14):626S.
10. Hu Z.Y., Zhao Y.S. Sex-dependent differences in cytochrome P450 3A activity as assessed by midazolam disposition in humans: a meta-analysis. Drug Metab Dispos 2010, 38(5):817-823.
11. O'Donnell P.H., Dolan M.E. Cancer pharmacoethnicity: ethnic differences in susceptibility to the effects of chemotherapy. Clin Cancer Res 2009, 15(15):4806-4814.
12. Mattison L.K., Fourie J., Desmond R.A., Modak A., Saif M.W., Diasio R.B. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 2006, 12(18):5491-5495.
13. Donelli M.G., Zucchetti M., Munzone E., D'Incalci M., Crosignani A. Pharmacokinetics of anticancer agents in patients with impaired liver function. Eur J Cancer 1998, 34(1):33-46.
14. Wang X.R., Qu Z.Q., Li X.D., et al. Activity of sulfotransferase 1A1 is dramatically upregulated in patients with hepatocellular carcinoma secondary to chronic hepatitis B virus infection. Cancer Sci. 2010, 101(2):412-415.
15. Rivory L.P., Slaviero K.A., Clarke S.J. Hepatic cytochrome P450 3A drug metabolism is reduced in cancer patients who have an acute-phase response. Br J Cancer 2002, 87(3):277-280.
16. Emery M.G., Fisher J.M., Chien J.Y., et al. CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease. Hepatology 2003, 38(2):428-435.
17. Abernethy D.R., Greenblatt D.J., Divoll M., Shader R.I. Enhanced glucuronide conjugation of drugs in obesity - studies of lorazepam, oxazepam, and acetaminophen. J Lab Clin Med 1983, 101(6):873-880.
18. O'Gorman P., McMillan D.C., McArdle C.S. Longitudinal study of weight, appetite, performance status, and inflammation in advanced gastrointestinal cancer. Nutr Cancer 1999, 35(2):127-129.
19. Beijnen J.H., Schellens J.H.M. Drug interactions in oncology. Lancet Oncol 2004, 5(8):489-496.
20. Engels F.K., ten Tije A.J., Baker S.D., et al. Effect of cytochrome P450 3A4 inhibition on the pharmacokinetics of docetaxel. Clin Pharmacol Ther 2004, 75(5):448-454.
21. Mathijssen R.H.J., Verweij J., de Bruijn P., Loos W.J., Sparreboom A. Effects of St. John's wort on irinotecan metabolism. J Natl Cancer Inst 2002, 94(16):1247-1249.
22. Streetman D.S., Bertino J.S., Nafziger A.N. Phenotyping of drug-metabolizing enzymes in adults: a review of in-vivo cytochrome P450 phenotyping probes. Pharmacogenetics 2000, 10(3):187-216.
23. de Jonge M.E., Huitema A.D., Schellens J.H., Rodenhuis S., Beijnen J.H. Individualised cancer chemotherapy: strategies and performance of prospective studies on therapeutic drug monitoring with dose adaptation: a review. Clin Pharmacokinet 2005, 44(2):147-173.
24. van Erp N.P., Guchelaar H.J., Ploeger B.A., Romijn J.A., den Hartigh J., Gelderblom H. Mitotane has a strong and a durable inducing effect on CYP3A4 activity. Eur J Endocrinol 2011, 164(4):621-626.
25. Goh B.C., Lee S.C., Wang L.Z., et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J Clin Oncol 2002, 20(17):3683-3690.
26. Fuhr U., Jetter A., Kirchheiner J. Appropriate phenotyping procedures for drug metabolizing enzymes and transporters in humans and their simultaneous use in the "cocktail" approach. Clin Pharmacol Ther 2007, 81(2):270-283.
27. Modak A.S. (13)C breath tests in personalized medicine: fiction or reality?. Exp Rev Mol Diagn 2009, 9(8):805-815.
28. Eap C.B., Buclin T., Cucchia G., et al. Oral administration of a low dose of midazolam (75μg) as an in vivo probe for CYP3A activity. Eur J Clin Pharmacol 2004, 60(4):237-246.
29. Peng C.C., Templeton I., Thummel K.E., Davis C., Kunze K.L., Isoherranen N. Evaluation of 6 beta-hydroxycortisol, 6 beta-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo. Clin Pharmacol Ther 2011, 89(6):888-895.
30. Diczfalusy U., Nylen H., Elander P., Bertilsson L. 4 beta-hydroxycholesterol, an endogenous marker of CYP3A4/5 activity in humans. Br J Clin Pharmacol 2011, 71(2):183-189.
31. Wrighton S.A., Stevens J.C. The Human Hepatic cytochromes-p450 involved in drug-metabolism. Crit Rev Toxicol 1992, 22(1):1-21.
32. Mo S.L., Liu Y.H., Duan W., Wei M.Q., Kanwar J.R., Zhou S.F. Substrate specificity, regulation, and polymorphism of human cytochrome P450 2B6. Curr Drug Metab 2009, 10(7):730-753.
33. de Jonge M.E., Huitema A.D.R., Rodenhuis S., Beijnen J.H. Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokinet 2005, 44(11):1135-1164.
34. Griskevicius L., Yasar U., Sandberg M., et al. Bioactivation of cyclophosphamide: the role of polymorphic CYP2C enzymes. Eur J Clin Pharmacol 2003, 59(2):103-109.
35. de Jonge M.E., Huitema A.D.R., van Dam S.M., Rodenhuis S., Beijnen J.H. Effects of co-medicated drugs on cyclophosphamide bioactivation in human liver microsomes. Anticancer Drugs 2005, 16(3):331-336.
36. Draft FDA guidance for industry. September 2006. Available from: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm072101.pdf.
37. Kirchheiner J., Klein C., Meineke I., et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics 2003, 13(10):619-626.
38. Kharasch E.D., Mitchell D., Coles R. Stereoselective bupropion hydroxylation as an in vivo phenotypic probe for cytochrome P4502B6 (CYP2B6) activity. J Clin Pharmacol 2008, 48(4):464-474.
39. Daily E.B., Aquilante C.L. Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics 2009, 10(9):1489-1510.
40. Henningsson A., Marsh S., Loos W.J., et al. Association of Cyp2C8, Cyp3A4, Cyp3A5, and Abcb1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res 2005, 11(22):8097-8104.
41. Chang T.K.H., Yu L., Goldstein J.A., Waxman D.J. Identification of the polymorphically expressed CYP2C19 and the wild-type CYP2C9-ILE359 allele as low-K-m catalysts of cyclophosphamide and ifosfamide activation. Pharmacogenetics 1997, 7(3):211-221.
42. Coller J.K., Krebsfaenger N., Klein K., et al. The influence of CYP2B6, CYP2C9 and CYP2D6 genotypes on the formation of the potent antioestrogen Z-4-hydroxy-tamoxifen in human liver. Br J Clin Pharmacol 2002, 54(2):157-167.
43. Zhou S.F., Zhou Z.W., Huang M. Polymorphisms of human cytochrome P450 2C9 and the functional relevance. Toxicology 2010, 278(2):165-188.
44. Ekhart C., Doodeman V.D., Rodenhuis S., Smits P.H.M., Beijnen J.H., Huitema A.D.R. Influence of polymorphisms of drug metabolizing enzymes (CYP2136, CYP2C9, CYPX19, CYP3A4, CYP3A5, GSTA1, GSTP1, ALDH1A1 and ALDH3A1) on the pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide. Pharmacogenet Genomics 2008, 18(6):515-523.
45. Gor P.P., Su H.I., Gray R.J., et al. Cyclophosphamide-metabolizing enzyme polymorphisms and survival outcomes after adjuvant chemotherapy for node-positive breast cancer: a retrospective cohort study. Breast Cancer Res 2010, 12(3).
46. Vormfelde S.V., Brockmoller J., Bauer S., et al. Relative impact of genotype and enzyme induction on the metabolic capacity of CYP2C9 in healthy volunteers. Clin Pharmacol Ther 2009, 86(1):54-61.
47. Shord S.S., Cavallari L.H., Viana M.A.G., et al. Cytochrome P4502C9 mediated metabolism in people with and without cancer. Int J Clin Pharmacol Ther 2008, 46(7):365-374.
48. Ando Y., Fuse E., Figg W.D. Thalidomide metabolism by the CYP2C subfamily. Clin Cancer Res 2002, 8(6):1964-1973.
49. Crewe H.K., Ellis S.W., Lennard M.S., Tucker G.T. Variable contribution of cytochromes P450 2D6, 2C9 and 3A4 to the 4-hydroxylation of tamoxifen by human liver microsomes. Biochem Pharmacol 1997, 53(2):171-178.
50. Helsby N.A., Lo W.Y., Sharples K., et al. CYP2C19 pharmacogenetics in advanced cancer: compromised function independent of genotype. Br J Cancer 2008, 99(8):1251-1255.
51. van Erp N.P., Gelderblom H., Guchelaar H.J. Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat Rev 2009, 35(8):692-706.
52. Dehal S.S., Kupfer D. CYP2D6 catalyzes tamoxifen 4-hydroxylation in human liver. Cancer Res 1997, 57(16):3402-3406.
53. Madlensky L., Natarajan L., Tchu S., et al. Tamoxifen metabolite concentrations, CYP2D6 genotype, and breast cancer outcomes. Clin Pharmacol Ther 2011, 89(5):718-725.
54. Jin Y., Desta Z., Stearns V., et al. CYP2D6 genotype, antidepressant use, and tamoxifen metabolism during adjuvant breast cancer treatment. J Natl Cancer Inst 2005, 97(1):30-39.
55. Frank D., Jaehde U., Fuhr U. Evaluation of probe drugs and pharmacokinetic metrics for CYP2D6 phenotyping. Eur J Clin Pharmacol 2007, 63(4):321-333.
56. Yu A.M., Haining R.L. Comparative contribution to dextromethorphan metabolism by cytochrome P450 isoforms in vitro: can dextromethorphan be used as a dual probe for both CYP2D6 and CYP3A activities?. Drug Metab Dispos 2001, 29(11):1514-1520.
57. de Graan A.J., Teunissen S.F., de Vos F.Y., et al. Dextromethorphan As a Phenotyping Test to Predict Endoxifen Exposure in Patients on Tamoxifen Treatment. J Clin Oncol 2011, 29(24):3240-3246.
58. Chugh R., Wagner T., Griffith K.A., et al. Assessment of ifosfamide pharmacokinetics, toxicity, and relation to CYP3A4 activity as measured by the erythromycin breath test in patients with sarcoma. Cancer 2007, 109(11):2315-2322.
59. Shou M., Martinet M., Korzekwa K.R., Krausz K.W., Gonzalez F.J., Gelboin H.V. Role of human cytochrome P450 3A4 and 3A5 in the metabolism of taxotere and its derivatives: enzyme specificity, interindividual distribution and metabolic contribution in human liver. Pharmacogenetics 1998, 8(5):391-401.
60. Kajita J., Kuwabara T., Kobayashi H., Kobayashi S. CYP3A4 is mainly responsibile for the metabolism of a new vinca alkaloid, vinorelbine, in human liver microsomes. Drug Metab Dispos 2000, 28(9):1121-1127.
61. Kehrer D.F.S., Mathijssen R.H.J., Verweij J., de Bruijn P., Sparreboom A. Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002, 20(14):3122-3129.
62. Kuehl P., Zhang J., Lin Y., et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001, 27(4):383-391.
63. Lamba J.K., Lin Y.S., Schuetz E.G., Thummel K.E. Genetic contribution to variable human CYP3A-mediated metabolism. Adv Drug Deliv Rev 2002, 54(10):1271-1294.
64. Watkins P.B., Murray S.A., Winkelman L.G., Heuman D.M., Wrighton S.A., Guzelian P.S. Erythromycin breath test as an assay of glucocorticoid-inducible liver cytochromes P-450. Studies in rats and patients. J Clin Invest 1989, 83(2):688-697.
65. Marre F., Sanderink G.J., de S.G., Gaillard C., Martinet M., Rahmani R. Hepatic biotransformation of docetaxel (taxotere) in vitro: involvement of the CYP3A subfamily in humans. Cancer Res 1996, 56(6):1296-1302.
66. Hirth J., Watkins P.B., Strawderman M., Schott A., Bruno R., Baker L.H. The effect of an individual's cytochrome CYP3A4 activity on docetaxel clearance. Clin Cancer Res 2000, 6(4):1255-1258.
67. Hurria A., Fleming M.T., Baker S.D., et al. Pharmacokinetics and toxicity of weekly docetaxel in older patients. Clin Cancer Res 2006, 12(20):6100-6105.
68. Schott A.F., Rae J.M., Griffith K.A., Hayes D.F., Sterns V., Baker L.H. Combination vinorelbine and capecitabine for metastatic breast cancer using a non-body surface area dosing scheme. Cancer Chemother Pharmacol 2006, 58(1):129-135.
69. Kurnik D., Wood A.J.J., Wilkinson G.R. The erythromycin breath test reflects P-glycoprotein function independently of cytochrome P450 3A activity. Clin Pharmacol Ther 2006, 80(3):228-234.
70. Wrighton S.A., Brian W.R., Sari M.A., et al. Studies on the expression and metabolic capabilities of human liver cytochrome P450IIIA5 (HLp3). Mol Pharmacol 1990, 38(2):207-213.
71. Ged C., Rouillon J.M., Pichard L., et al. The Increase in urinary-excretion of 6-beta-hydroxycortisol as a marker of human hepatic cytochrome-P450Iiia induction. Br J Clin Pharmacol 1989, 28(4):373-387.
72. Saima S., Furuie K., Yoshimoto H., Fukuda J., Hayashi T., Echizen H. The effects of rifampicin on the pharmacokinetics and pharmacodynamics of orally administered nilvadipine to healthy subjects. Br J Clin Pharmacol 2002, 53(2):203-206.
73. Tanaka C., Yin O.Q.P., Smith T., et al. Effects of rifampin and ketoconazole on the pharmacokinetics of nilotinib in healthy participants. J Clin Pharmacol 2011, 51(1):75-83.
74. Yamamoto N., Tamura T., Murakami H., et al. Randomized pharmacokinetic and pharmacodynamic study of docetaxel: dosing based on body-surface area compared with individualized dosing based on cytochrome P450 activity estimated using a urinary metabolite of exogenous cortisol. J Clin Oncol 2005, 23(6):1061-1069.
75. Gentile D.M., Tomlinson E.S., Maggs J.L., Park B.K., Back D.J. Dexamethasone metabolism by human liver in vitro. Metabolite identification and inhibition of 6-hydroxylation. J Pharmacol Exp Ther 1996, 277(1):105-112.
76. Puisset F., Dalenc F., Chatelut E., et al. Dexamethasone as a probe for vinorelbine clearance. Br J Clin Pharmacol 2005, 60(1):45-53.
77. Puisset F., Chatelut E., Dalenc F., et al. Dexamethasone as a probe for docetaxel clearance. Cancer Chemother Pharmacol 2004, 54(3):265-272.
78. Lee J.I., Chaves-Gnecco D., Amico J.A., Kroboth P.D., Wilson J.W., Frye R.F. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin Pharmacol Ther 2002, 72(6):718-728.
79. Yamaori S., Yamazaki H., Iwano S., et al. CYP3A5 Contributes significantly to CYP3A-mediated drug oxidations in liver microsomes from Japanese subjects. Drug Metab Pharmacokinet 2004, 19(2):120-129.
80. Fisher J.M., Wrighton S.A., Watkins P.B., et al. First-pass midazolam metabolism catalyzed by 1alpha, 25-dihydroxy vitamin D3-modified Caco-2 cell monolayers. J Pharmacol Exp Ther 1999, 289(2):1134-1142.
81. Kinirons M.T., O'Shea D., Kim R.B., et al. Failure of erythromycin breath test to correlate with midazolam clearance as a probe of cytochrome P4503A. Clin Pharmacol Ther 1999, 66(3):224-231.
82. Lown K.S., Thummel K.E., Benedict P.E., et al. The erythromycin breath test predicts the clearance of midazolam. Clin Pharmacol Ther 1995, 57(1):16-24.
83. Mathijssen R.H.J., de Jong F.A., van Schaik R.H.N., et al. Prediction of irinotecan pharmacokinetics by use of cytochrome p450 3A4 phenotyping probes. J Natl Cancer Inst 2004, 96(21):1585-1592.
84. van der Bol J.M., Mathijssen R.H.J., Creemers G.J.M., et al. A CYP3A4 phenotype-based dosing algorithm for individualized treatment of irinotecan. Clin Cancer Res 2010, 16(2):736-742.
85. Zamboni W.C., Combest A.J., Deloia J.A., et al. Pharmacologic and phenotypic study of docetaxel in patients with ovarian or primary peritoneal cancer. Cancer Chemother Pharmacol 2011, 68(5):1255-1262.
86. Li J., Karlsson M.O., Brahmer J., et al. CYP3A phenotyping approach to predict systemic exposure to EGFR tyrosine kinase inhibitors. J Natl Cancer Inst 2006, 98(23):1714-1723.
87. Gurney H., Wong M., Balleine R.L., et al. Imatinib disposition and ABCB1 (MDR1, p-glycoprotein) genotype. Clin Pharmacol Ther 2007, 82(1):33-40.
88. Green H., Skoglund K., Rommel F., Mirghani R.A., Lotfi K. CYP3A activity influences imatinib response in patients with chronic myeloid leukemia: a pilot study on in vivo CYP3A activity. Eur J Clin Pharmacol 2010, 66(4):383-386.
89. Heggie G.D., Sommadossi J.P., Cross D.S., Huster W.J., Diasio R.B. Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 1987, 47(8):2203-2206.
90. Deenen M.J., Tol J., Burylo A.M., et al. Relationship between single nucleotide polymorphisms and haplotypes in DPYD and toxicity and efficacy of capecitabine in advanced colorectal cancer. Clin Cancer Res 2011, 17(10):3455-3468.
91. Fleming R.A., Milano G., Thyss A., et al. Correlation between dihydropyrimidine dehydrogenase-activity in peripheral mononuclear-cells and systemic clearance of fluorouracil in cancer-patients. Cancer Res 1992, 52(10):2899-2902.
92. Ito S., Kawamura T., Inada M., et al. Physiologically based pharmacokinetic modelling of the three-step metabolism of pyrimidine using C-13-uracil as an in vivo probe. Br J Clin Pharmacol 2005, 60(6):584-593.
93. van Staveren M.C., Theeuwes-Oonk B., Guchelaar H.J., van Kuilenburg A.B., Maring J.G. Pharmacokinetics of orally administered uracil in healthy volunteers and in DPD-deficient patients, a possible tool for screening of DPD deficiency. Cancer Chemother Pharmacol 2011, 68(6):1611-1617.
94. Kristensen M.H., Pedersen P., Mejer J. The value of dihydrouracil/uracil plasma ratios in predicting 5-fluorouracil-related toxicity in colorectal cancer patients. J Int Med Res 2010, 38(4):1313-1323.
95. Gamelin E., Boissdron-Celle M., Guerin-Meyer V., et al. Correlation between uracil and dihydrouracil plasma ratio, fluorouracil (5-FU) pharmacokinetic parameters, and tolerance in patients with advanced colorectal cancer: a potential interest for predicting 5-FU toxicity and determining optimal 5-FU dosage. J Clin Oncol 1999, 17(4):1105-1110.
96. Zhou Z.W., Wang G.Q., Wan D.S., et al. The dihydrouracil/uracil ratios in plasma and toxicities of 5-fluorouracil-based adjuvant chemotherapy in colorectal cancer patients. Chemotherapy 2007, 53(2):127-131.
97. 2)-C-13 and plasma [2-C-13]dihydrouracil. Clin Cancer Res 2006, 12(2):549-555.
98. Scripture C.D., Figg W.D., Sparreboom A. The role of drug-metabolising enzymes in clinical responses to chemotherapy. Expert Opin Drug Metab Toxicol 2006, 2(1):17-25.
99. Evans W.E., Relling M.V. Pharmacogenomics: translating functional genomics into rational therapeutics. Science 1999, 286(5439):487-491.
100. Kiang T.K., Ensom M.H., Chang T.K. UDP-glucuronosyltransferases and clinical drug-drug interactions. Pharmacol Ther 2005, 106(1):97-132.
101. Miners J.O., Mackenzie P.I. Drug glucuronidation in humans. Pharmacol Ther 1991, 51(3):347-369.
102. Court M.H. Interindividual variability in hepatic drug glucuronidation: studies into the role of age, sex, enzyme inducers, and genetic polymorphism using the human liver bank as a model system. Drug Metab Rev 2010, 42(1):209-224.
103. Iyer L., King C.D., Whitington P.F., et al. Genetic predisposition to the metabolism of irinotecan (CPT-11) - role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998, 101(4):847-854.
104. Wen Z.M., Tallman M.N., Ali S.Y., Smith P.C. UDP-glucuronosyltransferase 1A1 is the principal enzyme responsible for etoposide glucuronidation in human liver and intestinal microsomes: structural characterization of phenolic and alcoholic glucuronides of etoposide and estimation of enzyme kinetics. Drug Metab Dispos 2007, 35(3):371-380.
105. Bosma P.J., Seppen J., Goldhoorn B., et al. Bilirubin UDP-glucuronosyltransferase-1 is the only relevant bilirubin glucuronidating isoform in man. J Biol Chem 1994, 269(27):17960-17964.
106. Bock K.W., Wiltfang J., Blume R., Ullrich D., Bircher J. Paracetamol as a test drug to determine glucuronide formation in man - effects of inducers and of smoking. Eur J Clin Pharmacol 1987, 31(6):677-683.
107. Gupta E., Mick R., Ramirez J., et al. Pharmacokinetic and pharmacodynamic evaluation of the topoisomerase inhibitor irinotecan in cancer patients. J Clin Oncol 1997, 15(4):1502-1510.
108. Mulders T.M.T., Venizelos V., Schoemaker R., Cohen A.F., Breimer D.D., Mulder G.J. Characterization of glutathione conjugation in humans - stereoselectivity in plasma elimination pharmacokinetics and urinary-excretion of (R)-2-bromoisovalerylurea and (S)-2-bromoisovalerylurea in healthy-volunteers. Clin Pharmacol Ther 1993, 53(1):49-58.
109. Booth R.A., Ansari M.T., Loit E., et al. Assessment of thiopurine S-methyltransferase activity in patients prescribed thiopurines: a systematic review. Ann Intern Med 2011, 154(12):U814-U872.
110. Menor C., Fueyo J.A., Escribano O., et al. Determination of thiopurine methyltransferase activity in human erythrocytes by high-performance liquid chromatography: comparison with the radiochemical method. Ther Drug Monit 2001, 23(5):536-541.
111. Cropp C.D., Yee S.W., Giacomini K.M. Genetic variation in drug transporters in ethnic populations. Clin Pharmacol Ther 2008, 84(3):412-416.
112. Ekhart C., Rodenhuis S., Smits P.H.M., Beijnen J.H., Huitema A.D.R. An overview of the relations between polymorphisms in drug metabolising enzymes and drug transporters and survival after cancer drug treatment. Cancer Treat Rev 2009, 35(1):18-31.
113. Ma J.D., Tsunoda S.M., Bertino J.S., Trivedi M., Beale K.K., Nafziger A.N. Evaluation of in vivo P-glycoprotein phenotyping probes a need for validation. Clin Pharmacokinet 2010, 49(4):223-237.
114. Wong M., Evans S., Rivory L.P., et al. Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer. Clin Pharmacol Ther 2005, 77(1):33-42.
115. Wong M., Balleine R.L., Blair E.Y.L., et al. Predictors of vinorelbine pharmacokinetics and pharmacodynamics in patients with cancer. J Clin Oncol 2006, 24(16):2448-2455.
116. Baker S.D., Verweij J., Rowinsky E.K., et al. Role of body surface area in dosing of investigational anticancer agents in adults, 1991-2001. J Natl Cancer Inst 2002, 94(24):1883-1888.
117. Gurney H. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. J Clin Oncol 1996, 14(9):2590-2611.
118. Irvin W.J., Walko C.M., Weck K.E., et al. Genotype-guided tamoxifen dosing increases active metabolite exposure in women with reduced CYP2D6 metabolism: a multicenter study. J Clin Oncol 2011, 29(24):3232-3239.
119. Borges S., Desta Z., Li L., et al. Quantitative effect of CYP2D6 genotype and inhibitors on tamoxifen metabolism: implication for optimization of breast cancer treatment. Clin Pharmacol Ther 2006, 80(1):61-74.
120. Borges S., Desta Z., Jin Y., et al. Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. J Clin Pharmacol 2010, 50(4):450-458.
121. Vermes A., Guchelaar H.J., Koopmans R.P. Individualization of cancer therapy based on cytochrome P450 polymorphism: a pharmacogenetic approach. Cancer Treat Rev 1997, 23(5-6):321-339.
122. Granvil C.P., Madan A., Sharkawi M., Parkinson A., Wainer I.W. Role of CYP2B6 and CYP3A4 in the in vitro N-dechloroethylation of (R)- and (S)-ifosfamide in human liver microsomes. Drug Metab Dispos 1999, 27(4):533-541.
123. Ambudkar S.V., Dey S., Hrycyna C.A., Ramachandra M., Pastan I., Gottesman M.M. Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu Rev Pharmacol Toxicol 1999, 39:361-398.
124. Michael M., Cullinane C., Hatzimihalis A., et al. Docetaxel pharmacokinetics and its correlation with two in vivo probes for cytochrome P450 enzymes: the C(14)-erythromycin breath test and the antipyrine clearance test. Cancer Chemother Pharmacol 2011.
125. He X., Hesse L.M., Hazarika S., et al. Evidence for oxazepam as an in vivo probe of UGT2B15: oxazepam clearance is reduced by UGT2B15 D85Y polymorphism but unaffected by UGT2B17 deletion. Br J Clin Pharmacol 2009, 68(5):721-730.
126. Hooker A.C., ten Tije A.J., Carducci M.A., et al. Population pharmacokinetic model for docetaxel in patients with varying degrees of liver function: incorporating cytochrome P450 3A activity measurements. Clin Pharmacol Ther 2008, 84(1):111-118.
127. Slaviero K.A., Clarke S.J., McLachlan A.J., Blair E.Y.L., Rivory L.P. Population pharmacokinetics of weekly docetaxel in patients with advanced cancer. Br J Clin Pharmacol 2004, 57(1):44-53.
128. Predictive value of drug elimination gene polymorphisms on clearance and dose adjustment of sunitinib in cancer patients (CLEARSUN). Available from: http://www.clinicaltrials.gov/ct2/show/NCT01098903?term=01098903&rank=1.